Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals REGN we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $152,500 and 6, calls, for a total amount of $296,619.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $1090.0 for Regeneron Pharmaceuticals during the past quarter.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 77.14 with a total volume of 57.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $520.0 to $1090.0 over the last 30 days.
Regeneron Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | SWEEP | BEARISH | 10/11/24 | $90.7 | $85.8 | $90.8 | $1090.00 | $90.8K | 11 | 10 |
| REGN | CALL | TRADE | NEUTRAL | 10/11/24 | $198.0 | $188.1 | $193.97 | $820.00 | $77.5K | 0 | 0 |
| REGN | CALL | TRADE | BULLISH | 01/16/26 | $527.0 | $517.0 | $527.0 | $520.00 | $52.7K | 0 | 1 |
| REGN | CALL | TRADE | BULLISH | 01/17/25 | $52.0 | $50.1 | $52.0 | $1040.00 | $52.0K | 286 | 10 |
| REGN | CALL | TRADE | BULLISH | 01/17/25 | $51.5 | $48.4 | $51.5 | $1040.00 | $51.5K | 286 | 20 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Where Is Regeneron Pharmaceuticals Standing Right Now?
- With a trading volume of 270,067, the price of REGN is down by -1.11%, reaching $1000.96.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 21 days from now.
What Analysts Are Saying About Regeneron Pharmaceuticals
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1170.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $1200. * Reflecting concerns, an analyst from BMO Capital lowers its rating to Outperform with a new price target of $1300. * An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $1015. * An analyst from RBC Capital has decided to maintain their Outperform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1260. * An analyst from Leerink Partners has revised its rating downward to Market Perform, adjusting the price target to $1077.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
